The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Arena Pharmaceuticals Inc

Nasdaq: ARNA
Last

(U.S.) $1.73

Today's change0.00 0.00%
Updated September 26 4:00 PM EDT. Delayed by at least 15 minutes.
 

Arena Pharmaceuticals Inc

Nasdaq: ARNA
Last

(U.S.) $1.73

Today's change0.00 0.00%
Updated September 26 4:00 PM EDT. Delayed by at least 15 minutes.

Arena Pharmaceuticals Inc closed at (U.S.)$1.73.

Over the last five days, shares have gained 2.37%, but are down 8.95% for the last year to date. Shares have underperformed the S&P 500 by 33.89% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $1.73
  • High--
  • Low--
  • Bid / Ask(U.S.) $1.58 / (U.S.) $1.80
  • YTD % change-8.95%
  • Volume0
  • Average volume (10-day)2,750,286
  • Average volume (1-month)1,764,918
  • Average volume (3-month)1,652,588
  • 52-week range(U.S.) $1.30 to (U.S.) $2.68
  • Beta-0.80
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.44
Updated September 26 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-291.35%

Although this company's net profit margin is negative, it is above the industry average and implies that Arena Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015
Revenue101089
Total other revenue--------
Total revenue101089
Gross profit7656
Total cost of revenue3433
Total operating expense36293734
Selling / general / administrative97109
Research & development19192022
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)5--4--
Other operating expenses, total--------
Operating income-26-19-29-25
Interest income (expense), net non-operating-2-2-2-2
Gain (loss) on sale of assets--------
Other--------
Income before tax-27-22-30-26
Income after tax-27-22-30-26
Income tax, total--------
Net income-27-22-30-26
Total adjustments to net income--------
Net income before extra. items-27-22-30-26
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-27-22-30-26
Inc. avail. to common incl. extra. items-27-22-30-26
Diluted net income-27-22-30-26
Dilution adjustment00--0
Diluted weighted average shares243243243242
Diluted EPS excluding extraordinary itemsvalue per share-0.11-0.09-0.13-0.11
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.09-0.09-0.11-0.11